Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant autologous tumor-loaded dendritic cell vaccination in resected stage IV rare cancers
2019-000793-27Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- May 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aldesleukin in head and neck squamous cell carcinoma (HNSCC), apudoma (NET) and soft tissue sarcoma (STS), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Safety and Immunological efficacy. Started May 2021; status: active.
02
Drugs
aldesleukin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)apudoma (NET)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2019-000793-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000793-27.